Drugs / SG1906
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05857332 | May 2023 → Feb 2027 expected | cancer of unknown primary site | Hangzhou Sumgen Biotech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SG1906 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05857332 ↗ |
| Route | Intravenous | “SG1906 monotherapy intravenous (IV) infusion” NCT05857332 ↗ |